A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with *FLT3*-ITD mutations

Mark J. Levis,¹ Alexander E. Perl,² Jessica K. Altman,³ Christopher D. Gocke,¹ Erkut Bahceci,⁴ Jason Hill,⁴ Chaofeng Liu,⁴ Zhiyi Xie,⁵ Andrew R. Carson,⁵ Valerie McClain,⁵ Timothy T. Stenzel,⁵ and Jeffrey E. Miller⁵

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; ²University of Pennsylvania–Abramson Comprehensive Cancer Center, Philadelphia, PA; ³Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; ⁴Astellas Pharma Global Development, Northbrook, IL; and

⁵Inivoscribe, Inc, San Diego, CA

Key Points

- A sensitive and specific assay was developed for detection of MRD in patients with AML who harbor *FLT3*-ITD mutations.
- This standardized assay is readily available and may be used to guide therapy decisions in patients with AML.

Internal tandem duplications in *fms-like tyrosine kinase 3* (*FLT3*-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in *FLT3*-ITD mutated AML could guide therapy decisions. Existing assays for MRD in *FLT3*-ITD AML have not been particularly useful because of limited sensitivity. We developed a sensitive and specific MRD assay for *FLT3*-ITD mutations using next-generation sequencing. The initial validation of this assay was performed by spiking fixed amounts of mutant DNA into wild-type DNA to establish a sensitivity of detection equivalent to ≥ 1 *FLT3*-ITD-containing cell in 10 000, with a minimum input of 100 000 cell equivalents of DNA. We subsequently validated the assay in bone marrow samples from patients with *FLT3*-ITD AML in remission. Finally, we analyzed bone marrow samples from 80 patients with *FLT3*-ITD relapsed/refractory AML participating in a trial of a novel *FLT3* inhibitor, gilteritinib, and demonstrated a relationship between the mutation burden, as detected by the assay, and overall survival. This novel MRD assay is specific and 2 orders of magnitude more sensitive than currently available polymerase chain reaction– or next-generation sequencing–based *FLT3*-ITD assays. The assay is being prospectively validated in ongoing randomized clinical trials.

Introduction

The ability to sensitively and accurately detect minimal residual disease (MRD) in patients with leukemia has proven to be useful in the clinical management of select disease subtypes and can potentially facilitate the development of new therapies. For example, *BCR-ABL* transcript levels are routinely used in the management of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia in which *BCR-ABL* transcript levels define optimal treatment response, serve as a marker for therapeutic resistance, and determine the need for treatment changes or more aggressive therapeutic strategies.^{1,2} To ensure clinical relevance, such measurements require a readily performed, robust, and harmonized assay for MRD detection and universal quantification. Significant progress has been made in the development of clinically useful and generalizable assays for MRD detection in adult acute myeloid leukemia (AML) using flow cytometry– and molecular-based approaches.^{3–6} However, despite its promise, the widespread use of MRD evaluation in AML remains limited by cross-center validation concerns, technical limitations of next-generation sequencing (NGS) for detection of point mutations, and the heterogeneity and relatively low incidence of specific gene fusions.

Internal tandem duplications in *fms-like tyrosine kinase 3* (*FLT3*-ITDs) are among the most common mutations found in AML and are associated with an aggressive disease phenotype and high relapse rates after traditional cytotoxic chemotherapy, which explains why such patients are referred for allogeneic transplant early in the disease course.^{7,8} Several *FLT3* tyrosine kinase inhibitors (TKIs) are in active development; 1 TKI (midostaurin) has been recently approved for the treatment of *FLT3* mutation-positive AML when administered in combination with standard induction chemotherapy.⁹⁻¹³ When administered as monotherapy for relapsed *FLT3*-mutated AML, *FLT3* TKIs can induce differentiation or cytotoxicity in marrow blasts, often resulting in responses that do not conform to the standard International Working Group (IWG) criteria for complete remission (CR).^{14,15} Indeed, the benefits of the most common type of response induced by *FLT3* TKIs, CR with incomplete hematological recovery (CRI), have been difficult to quantify.

Initial response rates to intensive chemotherapy are quite high in patients with *FLT3*-ITD AML; although a substantial number of these patients will ultimately relapse if not transplanted, this is by no means uniformly seen. Therefore, the availability of a sensitive and specific *FLT3*-ITD mutation assay to be used for patients in clinical remission that allows for detection of MRD would present a significant advantage for clinicians, because it could help to guide decisions about whether patients should undergo transplantation, as well as potentially whether *FLT3* inhibitors should be administered as maintenance therapy following intensive chemotherapy or transplantation. Furthermore, the ability to sensitively and accurately determine the mutated *FLT3* allele burden in a given bone marrow sample could be used to better characterize responses to *FLT3* TKIs.

Although several groups have reported the development of MRD assays for *FLT3*-ITD AML, none of these diagnostics have been developed in concert with bioinformatics software under a quality system with the intent of being submitted to regulatory authorities as a harmonized assay available to the international community. Polymerase chain reaction (PCR)-based assays for MRD in *FLT3*-ITD AML have a detection sensitivity of 1 mutant cell out of 100, at best.^{16,17} Moreover, having 2 unique templates (ie, a wild-type allele and a longer ITD-mutated allele) within a single reaction tube can potentially result in greater amplification of the shorter wild-type allele. This PCR bias based on template differences is a well-described phenomenon¹⁸ that has prevented application of PCR techniques to *FLT3*-ITD-mutated AML in a manner similar to that of *BCR-ABL*.

Here, we report the development of an *FLT3*-ITD assay using an improved PCR methodology with enhanced linearity across the range of *FLT3*-ITD allele burden, combined with an NGS platform that is sensitive, specific, and can be used to detect the presence of MRD in patients with *FLT3* mutation-positive AML achieving morphologic remission. Furthermore, we demonstrate the usefulness of this assay in characterizing clinical responses induced by *FLT3* inhibition in patients with *FLT3*-mutated relapsed/refractory (R/R) AML.

Methods

FLT3-ITD MRD assay

Exons 14 and 15 of the *FLT3* gene were amplified by PCR. The PCR primers, which contained gene-specific regions adapted

from previously published reports,¹⁶ were coupled with sequencing adaptors and proprietary barcodes (Invivoscribe, Inc., San Diego, CA) to lessen amplification bias and to allow amplified products from multiple samples to be run simultaneously on an Illumina MiSeq sequencer (Illumina, San Diego, CA). The PCR products were purified with an Agencourt Ampure XP kit (Beckman Coulter, Pasadena, CA), and the DNA concentration of the purified amplicons was quantified with a LabChip GX system (PerkinElmer, Waltham, MA). Libraries were prepared from purified amplicons and sequenced on a MiSeq sequencer (Illumina), according to the manufacturer's instructions. Sequencing data were analyzed using proprietary software developed by Invivoscribe. Validation of linearity was performed by testing a serial dilution of fixed amounts of mutant DNA (from cell line A: MV4-11 cells, 30-bp homozygous ITD and cell line B: PL-21 cells, 126-bp heterozygous ITD) that were spiked into wild-type DNA from Jurkat cells. To establish sensitivity sufficient to detect ≥ 1 *FLT3*-ITD-containing cell in 10 000, a minimum input of 100 000 cell equivalents of DNA (660 ng) was tested. The DNA input for the linearity validation and the clinical samples was 700 ng.

NPM1 assay

The assay for detection of *nucleophosmin* (*NPM1*) mutations was based on a published method.¹⁹ RNA was prepared using QIAGEN RNeasy columns (QIAGEN, Valencia, CA) and reverse transcribed. A semiquantitative multiplex PCR reaction was performed using primers specific for mutated *NPM1* (Asuragen Signature LTx; Asuragen, Austin, TX).²⁰ The fluorescently labeled PCR products were identified by hybridization to mutation-specific beads, followed by flow cytometry detection of the products (Luminex, Austin, TX). Amplified glyceraldehyde 3-phosphate dehydrogenase mRNA served as a control to verify sample quality.

Clinical flow cytometry

Bone marrow aspirates from AML patients with *FLT3*-ITD mutations treated at Johns Hopkins Hospital (Baltimore, MD) were analyzed by 6-color multiparameter flow cytometry (for a leukemia-associated phenotype), as previously described.¹⁴ The estimated sensitivity of this technique was the detection of 1 leukemia cell of 1000 (0.1%).

Patient samples

All patients provided their informed consent, according to the guidelines of the Declaration of Helsinki, and approval from the institutional review board was obtained. Bone marrow aspirates from patients with AML (with and without *FLT3*-ITD mutations) were collected in heparinized vacutainer tubes. All patients tested were in clinical remission according to IWG criteria.²¹ DNA was isolated using QIAquick columns (QIAGEN), according to the manufacturer's instructions. Extracted DNA was analyzed at 2 sites in the United States: the Molecular Diagnostics Laboratory at Johns Hopkins Hospital and Invivoscribe, Inc. The conventional assay for *FLT3* mutations, in which DNA was amplified by PCR and separated by capillary electrophoresis (CE), was performed at Johns Hopkins Hospital, as previously described.¹⁶ The MRD assay was developed by and performed at Invivoscribe, Inc. The *FLT3* mutant/wild-type allelic ratios (derived from the CE assay performed at Johns Hopkins University) were expressed as the mutant fraction of total alleles (ie, ITD/ITD + wild-type $\times$ 100%). The site conducting the MRD assay (Invivoscribe, Inc.) was blind to the

Table 1. Spike-in validation of MRD assay

Cell line DNA	Expected VAF	Total replicates, N	Replicates ITD not detected	Replicates ITD detected	Sensitivity, %
Cell line A (30-bp ITD)	1E-02	4	0	4	100.00
	1E-03	4	0	4	100.00
	1E-04	36	0	36	100.00
	5E-05	68	0	68	100.00
Cell line B (126-bp ITD)	1E-02	4	0	4	100.00
	1E-03	4	0	4	100.00
	1E-04	36	1	35	97.22
	5E-05	68	19	49	72.06
Jurkat cell line (WT)	0	38	38	0	N/A

DNA from 2 cell lines with known *FLT3*-ITD mutations (cell line A: MV4-11, 30 bp homozygous; cell line B: PL-21, 126 bp heterozygous) was diluted into background DNA from an *FLT3* wild-type cell line (Jurkat) at the ratios shown ("Expected"). The VAF is the mutation to total reads from the MRD assay and is shown for each cell line used as a source of mutant DNA ("Detected").

N/A, not applicable; WT, wild-type.

clinical information regarding the sample. No information was provided regarding the presence or absence of *FLT3*-ITD mutations, mutation length, or the mutant/wild-type allelic ratio.

Clinical trial samples

Bone marrow samples were obtained from patients who participated in the CHRYSALIS study (www.clinicaltrials.gov NCT02014558), which was a phase 1/2 study of the novel *FLT3* TKI gilteritinib (ASP2215) in R/R AML.¹¹ Overall, 137 patients treated in this trial had *FLT3*-ITD mutations and received *FLT3*-inhibitory oral doses of 120 or 200 mg/d gilteritinib.¹¹ Of these 137 patients, 80 had bone marrow aspirates collected at baseline and at ≥ 1 time point after starting treatment with gilteritinib. The primary ITD was defined as the ITD with the highest variant allele frequency (VAF; defined as *FLT3* mutant reads: *FLT3* total reads) at baseline in a given sample. When multiple ITDs were detected within a sample, the sum of ITDs was used. Responses were classified as CR (ie, bone marrow regenerating normal hematopoietic stem cells and achievement of a morphologic leukemia-free state with no evidence of extramedullary leukemia; absolute neutrophil count $>1 \times 10^9/L$, a platelet count $\geq 100 \times 10^9/L$, and normal marrow differential with $<5\%$ blasts, independent of red blood cell and platelet transfusion), complete remission with incomplete platelet recovery (CRp; ie, response meets all CR criteria except that platelet count is $<1 \times 10^9/L$), and CRi (ie, response meets all CR criteria except that the subject experiences residual neutropenia [absolute neutrophil count $<1 \times 10^9/L$], with or without complete platelet recovery, and does not require transfusion independence). Further details regarding the CHRYSALIS study design, patient population, and outcomes are outlined in Perl et al.¹¹

Results

Limit of detection and linearity of contrived samples

The experimental data for the MRD assay are presented in Table 1 and Figure 1. As shown in Figure 1, the linearity of the assay is excellent, in the range of 10^{-2} to 10^{-5} ($R^2 = +0.98-0.99$). The reliable limit of detection was 5×10^{-5} , although in some cases an ITD mutation was detected at even lower levels. No mutation was detected in the testing of 38 replicates of an *FLT3*-ITD-negative sample, indicating that the limit of blank is 0. No-template controls,

which were included in each amplification run, yielded no-sequencing reads.

Clinical samples

To validate the MRD assay for clinical use, we analyzed bone marrow aspirates from 15 patients with *FLT3*-ITD AML. These samples were collected at different points during the course of therapy (eg, after induction therapy or after allogeneic transplant). At the time of bone marrow collection for MRD analysis, all 15 patients were in a clinical remission, according to IWG criteria.²¹ For all 15 samples, the CE assay for the *FLT3*-ITD mutation was negative, and no cell with a leukemia-associated phenotype could be identified using 6-color multiparameter flow cytometry. The clinical and MRD data for these patients are summarized in supplemental Table 1.

The first 4 patients (supplemental Table 1, patients 1-4) had been diagnosed with *FLT3*-ITD-mutated AML and had achieved remission after intensive cytarabine-based induction chemotherapy. The bone marrow aspirate samples analyzed were collected at the time of hematologic recovery to confirm CR. Because AML is rarely cured with induction therapy alone, these patients would be expected to have some level of residual disease within the bone marrow. The MRD assay identified *FLT3*-ITD mutations in all 4 cases, at VAFs ranging from 1.35×10^{-5} to 3.33×10^{-4} . The investigators who performed the MRD assay under blinded conditions correctly identified the abnormal insertion sequence matching the exact lengths of the ITD for each patient that had been initially detected by the CE assay at diagnosis, thereby providing confirmation of the specificity of the assay.

Patients in the next group (supplemental Table 1, patients 5-7) were considered clinically more high risk. Bone marrow aspirate samples were collected while these patients were in their second or third remission. *FLT3*-ITD mutations were detected in all 3 patients at VAFs ranging from 1.38×10^{-6} to 1.11×10^{-4} . Patient 5 underwent a second allogeneic hematopoietic stem cell transplant (HSCT) following sample collection (ie, the bone marrow biopsy performed to confirm remission immediately prior to the transplant) and remained in remission while on sorafenib maintenance therapy 2.5 years after transplantation. Patients 6 and 7 received no further therapy, and both relapsed and died.

Figure 1. Linearity of NGS-MRD assay. The NGS-MRD assay was performed using mutant DNA spiked into wild-type DNA. Two cell lines, each expressing different ITD mutations, were used (cell line A [MV4-11], 30 bp and cell line B [PL-21], 126 bp). The results of the assay were plotted after linear conversion as detected vs expected. Results of regression analysis are shown.

For the next set of patients (supplemental Table 1, patients 8-13), we sought to determine whether an *FLT3*-ITD mutation could persist during a durable remission. Each of these patients had undergone allogeneic HSCT 24-48 months prior to sample collection; in each case, the MRD assay was negative. These results suggest that the MRD assay can be used to identify patients in whom durable remission has been achieved.

Finally, we selected 2 patients (supplemental Table 1, patients 14 and 15) with *FLT3*-ITD AML who had relapsed following allogeneic HSCT. We obtained banked DNA that had been isolated from bone marrow aspirates collected at 2 months (patient 14) and 6 months (patient 15) after transplantation. It should be noted that, for both of these cases, the CE assay was negative for *FLT3*-ITD mutations,

and the chimerism in the unfractionated bone marrow and peripheral blood T-cell compartments was 100% donor. The MRD assay correctly identified the length of the corresponding *FLT3*-ITD mutation at VAFs of 1.04×10^{-4} to 3.67×10^{-3} . Both patients relapsed 2 months after these samples were collected.

NPM1 mutations had been identified at diagnosis in 11 of the 15 patients. By using the same *NPM1* mutation assay that was performed at diagnosis in these 11 patient samples, an *NPM1* mutation was identified at a low level in 1 patient (supplemental Table 1, patient 7) but was not detected in the other 9 patients (patients 1-4, 8, 10-12, and 14).

Relationship between MRD and survival

The presence of detectable MRD in patients with AML who are in remission correlates with an increased risk for relapse and reduced overall survival (OS).³⁻⁶ We analyzed bone marrow aspirates collected from patients with *FLT3*-ITD mutation-positive AML who were treated with the novel oral *FLT3* inhibitor, gilteritinib, in a clinical trial (2215-CL-0101; NCT02014558).¹¹ In this trial, adult patients with R/R AML were treated with oral gilteritinib as a single agent in 1 of 7 dose-escalation cohorts.¹¹ Doses of 120 and 200 mg/d resulted in complete inhibition of *FLT3* ex vivo, as measured by the plasma-inhibitory assay.²² Of the 137 *FLT3*-ITD-mutated patients who had received gilteritinib doses of 120 or 200 mg/d, 80 patients who had bone marrow aspirates at baseline and ≥ 1 additional time point were included in this analysis. Thirty-six of these 80 patients had >1 ITD. The composite CR rate (CRc; defined as CR plus CRi plus CRp) for these 80 patients was 55% (44 patients). MRD (defined as an *FLT3*-ITD VAF $>10^{-4}$) was detected in 33 of these 44 patients (summarized in supplemental Table 2); 15 of these 44 patients who had achieved CRc had >1 ITD. The rate of MRD negativity was the same when ITDs were summed and when only the primary ITDs were used. Figure 2 shows that the survival of these MRD-positive patients is significantly worse than in those with a VAF $\leq 10^{-4}$, which demonstrates that gilteritinib can induce deep molecular responses, as measured by a highly sensitive MRD assay, in this patient population.

Figure 2. OS for subjects achieving remission in the CHRYSALIS study (ASP2215-CL-0101) according to detectable MRD. Kaplan-Meier analysis of survival for subjects treated with *FLT3*-inhibitory doses of gilteritinib (ASP2215) who achieved a CR, CRi, or CRp, according to the presence or absence of MRD detected by the NGS-MRD assay after treatment. MRD is defined as *FLT3*-ITD VAF $\geq 10^{-4}$. CI, confidence interval; NA, not achieved.

Table 2. OS for subjects in the CHRYSALIS study (ASP2215-CL-0101)

Molecular response	Achieved a molecular response		Did not achieve a molecular response		P
	n	Median OS (95% CI), d	n	Median OS (95% CI), d	
ITD VAF $\leq 10^{-2}$	20	417 (246–NA)	60	199 (142–234)	<.001
ITD VAF $\leq 10^{-3}$	18	417 (228–NA)	62	213 (143–264)	.003
ITD VAF $\leq 10^{-4}$ (MRD negative)	13	417 (228–NA)	67	213 (144–264)	.002

Pre- and posttreatment bone marrow samples were available from 80 patients with *FLT3*-ITD AML treated with *FLT3*-inhibitory doses of gilteritinib (ASP2215; 120 or 200 mg/d). A comparison was made between patients achieving a molecular response (*FLT3*-ITD VAF $\leq 10^{-2}$, $\leq 10^{-3}$, or negative as defined by ITD VAF $\leq 10^{-4}$) by the MRD assay and those not achieving a molecular response by the MRD assay. The *P* values were determined by the log-rank test.

Relationship between *FLT3* variant allele frequency and survival

The NGS-based MRD assay for *FLT3*-ITD mutations was used to further characterize the molecular responses of patients treated with gilteritinib by examining the correlation between *FLT3*-ITD VAF and survival. Of the 80 patients from whom pre- and posttreatment samples were obtained, 20 (25%) had an *FLT3*-ITD VAF (mutant to total reads) $\leq 10^{-2}$. When we empirically examined multiple cutoff points from 10^{-1} to 10^{-4} , we noted that a reduction in *FLT3*-ITD VAF (mutant to total reads) down to $\leq 10^{-2}$ was associated with a longer median OS. Therefore, we defined $\leq 10^{-2}$ as a molecular response. This level also approximates the lower limit of detectability for the CE assay, as performed at different institutions throughout the world.¹⁶ Of these 20 patients, 18 had an *FLT3*-ITD VAF $\leq 10^{-3}$ (major molecular response), and 13 had an *FLT3*-ITD VAF $\leq 10^{-4}$ (MRD-negative status). The median time to achieve the minimum VAF was 57 days. Patients who had a molecular response, as

defined by an *FLT3*-ITD VAF $\leq 10^{-2}$, 10^{-3} , or 10^{-4} , had significantly longer median OS than those who did not (*P* < .001, Table 2; Figure 3).

Discussion

We have described the development of a novel NGS-based sensitive and highly specific MRD assay to detect *FLT3*-ITD mutations in patients with AML. This assay differs from other widely used NGS assays for AML mutations in that it starts with a PCR amplification step and is followed by NGS using a unique software program. Unlike most AML driver mutations, *FLT3*-ITD mutations consist of variable-length inserts of nucleotide sequences, which are not readily amenable to analysis by the conventional NGS algorithms. PCR, by itself, lacks the necessary sensitivity because of competition from the wild-type allele (unless patient-specific primers are used). This NGS-based MRD assay detected *FLT3*-ITD mutations in patients with AML who were in remission, including patients with *FLT3*-ITD allele burdens that fell below the range of linearity of the assay. It should also be noted that the assay was found to be more sensitive than conventional reverse-transcription PCR-based assays for *NPM1* performed at Johns Hopkins Hospital using a published methodology.¹⁹

The MRD assay described here fulfills the requirements for a test that can be used by any clinician treating an AML patient with an *FLT3*-ITD mutation. This MRD assay is sensitive, specific, standardized, and is commercially available and accessible to any practitioner.²³ Although there have been a number of other reported assays for detecting and monitoring *FLT3*-ITD mutations, these have the disadvantages of lacking sensitivity, being overly cumbersome, or not being publicly available.^{17,24–26} Midostaurin, a TKI with activity against *FLT3*,²⁷ was recently granted regulatory approval in the United States for the treatment of *FLT3*-mutated AML,²⁸ and several *FLT3* inhibitors have entered pivotal trials. Therefore, the introduction of this assay is timely, because the future use of these agents could be guided by the presence or absence of detectable

Figure 3. OS for subjects in the CHRYSALIS study (ASP2215-CL-0101) according to molecular response.

Kaplan-Meier analysis of survival for subjects treated with *FLT3*-inhibitory doses of gilteritinib (ASP2215), according to ITD VAF detected by the NGS-MRD assay after treatment.

MRD (or VAF in patients with incomplete responses) in patients with *FLT3*-ITD mutations. In fact, this assay will be used to measure MRD as a secondary end point in a pivotal trial of the novel *FLT3* inhibitor gilteritinib administered as maintenance therapy after allogeneic HSCT (BMT-CTN 1506/Morpho; NCT02997202). The primary end point of BMT-CTN1506 is relapse-free survival, which necessitates a prolonged clinical study. The study will assess whether there is a relationship between MRD and survival. These types of studies may substantiate further use of MRD measurement as an end point, thereby offering a potentially expeditious route to the development and approval of new drugs for *FLT3*-ITD AML.

With regard to the important issue of whether an *FLT3*-ITD mutation is a suitable target for monitoring MRD, there is a general consensus that *FLT3*-ITD mutations tend to occur relatively late in leukemogenesis^{29,30} and can be “unstable,” such that their presence between diagnosis and relapse may be discordant.^{31,32} Alternatively, so-called “founder mutations,” such as *DNMT3a* or *TET2*, are less useful as markers of MRD, because they often define clonal hematopoiesis but not necessarily malignant hematopoiesis.^{33,34} Furthermore, lesions in *DNMT3a* and *TET2* are often missense mutations that may also be present as background noise in an amplification reaction. *NPM1* mutations have clear potential for MRD assessment,^{6,35} but only about half of the patients with an *FLT3*-ITD mutation have an *NPM1* mutation. When comparing *FLT3*-ITD mutations and other mutations as an MRD target, an apparent advantage is that each patient's *FLT3*-ITD mutation is a unique length. Detecting an *FLT3*-ITD mutation that is the exact sequence found in the diagnostic sample confers a distinct degree of specificity in this assay. If the *FLT3*-ITD mutation that was present at diagnosis is detected in a bone marrow sample, it likely represents the disease.

Finally, although flow cytometry–based assays are well established and have been used to successfully detect MRD in AML patients (including in *FLT3*-ITD AML),^{36,37} expanding their use in standardized fashion across multiple institutions in different countries (as required in a multicenter clinical trial) has proven to be challenging. The MRD assay described herein will be prospectively tested as a secondary end point in an international multicenter trial.

References

1. Yeung DT, Mauro MJ. Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *Hematology Am Soc Hematol Educ Program*. 2014;2014:240-243.
2. Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. *Hematology Am Soc Hematol Educ Program*. 2014;2014:244-249.
3. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood*. 2013;122(10):1813-1821.
4. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol*. 2013;31(31):3889-3897.
5. Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*. 2013;121(12):2213-2223.
6. Ivey A, Hills RK, Simpson MA, et al; UK National Cancer Research Institute AML Working Group. Assessment of minimal residual disease in standard-risk AML. *N Engl J Med*. 2016;374(5):422-433.
7. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in *N Engl J Med* 2013;369(1):98]. *N Engl J Med*. 2013;368(22):2059-2074.
8. Levis M. *FLT3* mutations in acute myeloid leukemia: what is the best approach in 2013? *Hematology Am Soc Hematol Educ Program*. 2013;2013:220-226.

Acknowledgments

This work was funded by Astellas Pharma Global Development, Inc. Editorial support for this manuscript was provided by Succinct Choice Medical Communications (Chicago, IL) and was funded by Astellas Pharma, Inc. M.J.L. was supported by a grant from the National Institutes of Health, National Cancer Institute (NCI Leukemia SPORE P50 CA100632).

The *FLT3*-ITD MRD assay was developed and performed by Invivoscribe, Inc.

Authorship

Contribution: M.J.L., T.T.S., and J.E.M. designed the study, performed experiments, analyzed the data, and wrote the manuscript; A.E.P., J.K.A., and E.B. analyzed data and edited the manuscript; J.H. and C.L. analyzed the data, performed statistical analyses, and edited the manuscript; and C.D.G., Z.X., A.R.C., and V.M. performed experiments, analyzed the data, and edited the manuscript.

Conflict-of-interest disclosure: M.J.L. has received consultancy fees and research funding from Astellas and Novartis, honoraria from Daiichi-Sankyo and Novartis, and research funding from Fujifilm and Millenium Pharmaceuticals/Takeda Pharmaceuticals. A.E.P. has received consultancy fees from Astellas, Daiichi-Sankyo, Novartis, Pfizer, and Arog Pharmaceuticals and has participated in advisory boards for Actinium Pharmaceuticals and Asana Biosciences. J.K.A. has received consultancy fees from Astellas, Syros, Bristol-Myers Squibb, Celgene, Celgene, Novartis, and Janssen Pharmaceuticals and has served as an educational speaker for the American Society of Hematology and the National Comprehensive Cancer Network. J.H., C.L., and E.B. are employees of Astellas Pharma, Inc. J.H. has ownership of Ligacept, LLC and patents (US7852995B2 [issued] and W02013163419A1 [pending]). A.R.C., J.E.M., T.T.S., V.M., and Z.X. are employees of Invivoscribe, Inc. C.D.G. declares no competing financial interests.

Correspondence: Mark J. Levis, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans St, Room 2M44, Baltimore, MD 21287; e-mail: levisma@jhmi.edu.

9. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. *J Clin Oncol*. 2013;31(29):3681-3687.
10. Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. *Blood*. 2014;123(1):94-100.
11. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. *Lancet Oncol*. 2017;18(8):1061-1075.
12. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med*. 2017;377(5):454-464.
13. RYDAPT (midostaurin) for oral use. US Food and Drug Administration Label. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf. Accessed 20 September 2017.
14. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. *Blood*. 2012;120(20):4205-4214.
15. Nybakken GE, Canaani J, Roy D, et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. *Leukemia*. 2016;30(6):1422-1425.
16. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. *J Mol Diagn*. 2003;5(2):96-102.
17. Gaballa S, Saliba R, Oran B, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. *Am J Hematol*. 2017;92(4):331-337.
18. Polz MF, Cavanaugh CM. Bias in template-to-product ratios in multitemplate PCR. *Appl Environ Microbiol*. 1998;64(10):3724-3730.
19. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood*. 2006;107(10):4011-4020.
20. Hafez M, Ye F, Jackson K, et al. Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations. *J Mol Diagn*. 2010;12(5):629-635.
21. Cheson BD, Bennett JM, Kopecky KJ, et al; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in *J Clin Oncol* 2004;22(3):576]. *J Clin Oncol*. 2003;21(24):4642-4649.
22. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. *Blood*. 2006;108(10):3477-3483.
23. Invivoscribe. FLT3 ITD MRD Testing by NGS. <https://www.invivoscribe.com/clinical-services/flt3-itd-mrd-testing-by-ngs>. Accessed 2 April 2018.
24. Thol F, Kölling B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. *Genes Chromosomes Cancer*. 2012;51(7):689-695.
25. Grunwald MR, Tseng LH, Lin MT, et al. Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. *Biol Blood Marrow Transplant*. 2014;20(12):1989-1995.
26. Bibault JE, Figeac M, Hélevaut N, et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. *Oncotarget*. 2015;6(26):22812-22821.
27. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*. 2005;105(1):54-60.
28. The FDA approves new leukemia drug; expands use of current drug. *FDA Consum*. 2006;40(6):5.
29. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. *Blood*. 2002;100(5):1532-1542.
30. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell*. 2012;150(2):264-278.
31. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. *Blood*. 2002;100(7):2387-2392.
32. Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. *Leuk Lymphoma*. 2003;44(6):905-913.
33. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371(26):2477-2487.
34. Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. *Oncotarget*. 2015;6(39):42345-42353.
35. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J Clin Oncol*. 2011;29(19):2709-2716.
36. Hess CJ, Feller N, Denkers F, et al. Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. *Haematologica*. 2009;94(1):46-53.
37. Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. *Leukemia*. 2016;30(7):1456-1464.